Skip to main content

Advertisement

SpringerLink
Log in

Vitamin D in cancer: effects of pharmaceutical drugs on the vitamin D pharmacokinetics

  • Review
  • Published:
Journal of Pharmaceutical Investigation Aims and scope Submit manuscript

Abstract

Vitamin D is a fat-soluble vitamin and has reported anti-cancer and anti-inflammatory properties as well as bone homeostasis through the modulation of gene transcription and non-genomic signaling cascades. The purpose of this review is to summarize the available research on pharmacokinetics of vitamin D analogues, especially 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3, the active form of vitamin D3] and the interactions between vitamin D and pharmaceutical drugs used in patients with cancer. Hypercalcemia was the most frequently reported side effect that occurred in high doses of 1,25(OH)2D3. The half-life of 25(OH)D3 and/or 1,25(OH)2D3 was found to be impacted by cimetidine; rosuvastatin; prednisone and possibly some chemotherapy drugs. No unusual adverse effects in cancer patients were identified through this review beyond what is expected from high dose 1,25(OH)2D3 supplementation such as the inconvenience of high dose vitamin D. The supplementation with 1,25(OH)2D3 during chemotherapy appears to have a low risk of interaction while sufficient evidence is still lacking. Further interactions with vitamin D3 and the development of new dosage forms for the therapy with high doses of vitamin D3 need to be evaluated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW, Pinkel D (2000) Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 25:144–146

    Article  PubMed  CAS  Google Scholar 

  • Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR (2006) Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 57:234–240

    Article  PubMed  CAS  Google Scholar 

  • Avioli LV, Birge SJ, Lee SW (1968) Effects of prednisone on vitamin D metabolism in man. J Clin Endocrinol Metab 28:1341–1346

    Article  PubMed  CAS  Google Scholar 

  • Bao BY, Yao J, Lee YF (2006) 1alpha,25-Dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27:1883–1893

    Article  PubMed  CAS  Google Scholar 

  • Bareis P, Bises G, Bischof MG, Cross HS, Peterlik M (2001) 25-Hydroxyvitamin D metabolism in human colon cancer cells during tumor progression. Biochem Biophys Res Commun 285:1012–1017

    Article  PubMed  CAS  Google Scholar 

  • Beer TM, Munar M, Henner WD (2001) A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 91:2431–2439

    Article  PubMed  CAS  Google Scholar 

  • Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD (2003) Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21:123–128

    Article  PubMed  CAS  Google Scholar 

  • Beer TM, Javle M, Lam GN, Henner WD, Wong A, Trump DL (2005) Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res 11:7794–7799

    Article  PubMed  CAS  Google Scholar 

  • Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL (2007) Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol 59:581–587

    Article  PubMed  CAS  Google Scholar 

  • Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL (2002) Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 143:2508–2514

    PubMed  CAS  Google Scholar 

  • Berry D, Hypponen E (2011) Determinants of vitamin D status: focus on genetic variations. Curr Opin Nephrol Hypertens 20:331–336

    Article  PubMed  CAS  Google Scholar 

  • Boulard JC, Hanslik T, Alterescu R, Baglin A (1994) Symptomatic hypercalcemia after vitamin D-thiazide diuretics combination. Two cases in elderly women. Presse Med 23:96

    PubMed  CAS  Google Scholar 

  • Carlberg C, Dunlop TW, Frank C, Vaisanen S, Feldman D, Pike JW, Glorieux FH (2005) Vitamin D. Elsevier, San Diego

    Google Scholar 

  • Chaudhry M, Sundaram S, Gennings C, Carter H, Gewirtz DA (2001) The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells. Cancer Chemother Pharmacol 47:429–436

    Article  PubMed  CAS  Google Scholar 

  • Chen G, Kim SH, King AN, Zhao L, Simpson RU, Christensen PJ, Wang Z, Thomas DG, Giordano TJ, Lin L, Brenner DE, Beer DG, Ramnath N (2011) CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin Cancer Res 17:817–826

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Chung I, Han G, Seshadri M, Gillard BM, Yu WD, Foster BA, Trump DL, Johnson CS (2009) Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res 69:967–975

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Cohen HJ, Silberman HR, Tornyos K, Bartolucci AA (1984) Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. Blood 63:639–648

    PubMed  CAS  Google Scholar 

  • Colston KW, Chander SK, Mackay AG, Coombes RC (1992) Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44:693–702

    Article  PubMed  CAS  Google Scholar 

  • Colston KW, James SY, Ofori-Kuragu EA, Binderup L, Grant AG (1997) Vitamin D receptors and antiproliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br J Cancer 76:1017–1020

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Cross HS, Bises G, Lechner D, Manhardt T, Kallay E (2005) The Vitamin D endocrine system of the gut—its possible role in colorectal cancer prevention. J Steroid Biochem Mol Biol 97:121–128

    Article  PubMed  CAS  Google Scholar 

  • Deeb KK, Trump DL, Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev 7:684–700

    Article  CAS  Google Scholar 

  • DeLuca HF (2008) Evolution of our understanding of vitamin D. Nutr Rev 66:S73–S87

    Article  PubMed  Google Scholar 

  • Ertugrul DT, Yavuz B, Cil H, Ata N, Akin KO, Kucukazman M, Yalcin AA, Dal K, Yavuz BB, Tutal E (2011) STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25-hydroxyvitamin D. Cardiovasc Ther 29:146–152

    Article  PubMed  CAS  Google Scholar 

  • Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science 240:889–895

    Article  PubMed  CAS  Google Scholar 

  • Fakih MG, Trump DL, Muindi JR, Black JD, Bernardi RJ, Creaven PJ, Schwartz J, Brattain MG, Hutson A, French R, Sohnson CS (2007) A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin Cancer Res 13:1216–1223

    Article  PubMed  CAS  Google Scholar 

  • Fakih MG, Trump DL, Johnson CS, Tian L, Muindi J, Sunga AY (2009) Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. Int J Colorectal Dis 24:219–224

    Article  PubMed  PubMed Central  Google Scholar 

  • Farhan H, Wahala K, Cross HS (2005) Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J Steroid Biochem Mol Biol 84:423–429

    Article  Google Scholar 

  • Fernandez-Garcia NI, Palmer HG, Garcia M, Gonzalez-Martin A, del Rio M, Barettino D, Volpert O, Muñoz A, Jimenez B (2005) 1alpha,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene 24:6533–6544

    PubMed  CAS  Google Scholar 

  • Ferrero D, Bruno B, Pregno P, Stefani S, Larizza E, Ciravegna G, Luraschi A, Vietti-Ramus G, Schinco P, Bazzan M, Gallo E, Pileri A (1996) Combined differentiating therapy for myelodysplastic syndromes: a phase II study. Leuk Res 20:867–876

    Article  PubMed  CAS  Google Scholar 

  • Friedrich M, Rafi L, Mitschele T, Tilgen W, Schmidt W, Reichrath J (2003) Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res 164:239–246

    Article  PubMed  CAS  Google Scholar 

  • Gallagher JC, Goldgar D (1990) Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 1:649–655

    Article  Google Scholar 

  • Gao Y, Shimizu M, Yamada S, Ozaki Y, Aso T (1993) The effects of chemotherapy including cisplatin on vitamin D metabolism. Endocr J 40:737–742

    Article  PubMed  CAS  Google Scholar 

  • Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS (1997) Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 50:999–1006

    Article  PubMed  CAS  Google Scholar 

  • Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, Willett WC (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98:451–459

    Article  PubMed  CAS  Google Scholar 

  • Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M, Holick MF (2005) Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol 97:179–194

    Article  PubMed  CAS  Google Scholar 

  • Hellstrom E, Robèrt KH, Samuelsson J, Lindemalm C, Grimfors G, Kimby E, Oberg G, Winqvist I, Billström R, Carneskog J (1990) Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG). Eur J Haematol 45:255–261

    Article  PubMed  CAS  Google Scholar 

  • Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL (2001) Calcitriol (1α,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 7:1043–1051

    PubMed  CAS  Google Scholar 

  • Hershberger PA, McGuire TF, Yu WD, Zuhowski EG, Schellens JH, Egorin MJ, Trump DL, Johnson CS (2002) Cisplatin potentiates 1α,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther 1:821–829

    PubMed  CAS  Google Scholar 

  • Hmama Z, Nandan D, Sly L, Knutson KL, Herrera-Velit P, Reiner NE (1999) 1alpha,25-dihydroxyvitamin D(3)-induced myeloid cell differentiation is regulated by a vitamin D receptor-phosphatidylinositol 3-kinase signaling complex. J Exp Med 190:1583–1594

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Holick MF (1996) Vitamin D and bone health. J Nutr 126:S1159–S1164

    Google Scholar 

  • Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281

    Article  PubMed  CAS  Google Scholar 

  • Hsieh JC, Jurutka PW, Galligan MA, Terpening CM, Haussler CA, Samuels DS, Shimizu Y, Shimizu N, Haussler MR (1991) Human vitamin D receptor is selectively phosphorylated by protein kinase C on serine 51, a residue crucial to its trans-activation function. Proc Natl Acad Sci USA 88:9315–9319

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Jacot W, Pouderoux S, Thezenas S, Chapelle A, Bleuse JP, Romieu G, Lamy PJ (2012) Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat 2:709–711

    Article  Google Scholar 

  • Jiang F, Li P, Fornace AJ Jr, Nicosia SV, Bai W (2003) G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J Biol Chem 278:48030–48040

    Article  PubMed  CAS  Google Scholar 

  • Jones G (2008) Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 88:S582–S586

    Google Scholar 

  • Kim SH, Chen G, King AN, Jeon CK, Christensen PJ, Zhao L, Simpson RU, Thomas DG, Giordano TJ, Brenner DE, Hollis B, Beer DG, Ramnath N (2012) Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer 77:265–271

    Article  PubMed  PubMed Central  Google Scholar 

  • King AN, Beer DG, Christensen PJ, Simpson RU, Ramnath N (2010) The vitamin D/CYP24A1 story in cancer. Anticancer Agents Med Chem 10:312–324

    Article  Google Scholar 

  • Lang PO, Samaras N, Samaras D, Aspinall R (2013) How important is vitamin D in preventing infections? Osteoporos Int 24:1537–1553

    Article  PubMed  CAS  Google Scholar 

  • Lechner D, Bajna E, Adlercreutz H, Cross HS (2006) Genistein and 17beta-estradiol, but not equol, regulate vitamin D synthesis in human colon and breast cancer cells. Anticancer Res 26:2597–2603

    PubMed  CAS  Google Scholar 

  • Li P, Li C, Zhao X, Zhang X, Nicosia SV, Bai W (2004) p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J Biol Chem 279:25260–25267

    Article  PubMed  CAS  Google Scholar 

  • Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS (1997) Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 57:3759–3764

    PubMed  CAS  Google Scholar 

  • Losel R, Wehling M (2003) Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 4:46–56

    Article  PubMed  Google Scholar 

  • Ma Y, Yu WD, Trump DL, Johnson CS (2010) 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer 116:3294–3303

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE (2000) 1α,25-Dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87:214–220

    Article  PubMed  CAS  Google Scholar 

  • Masuda S, Byford V, Arabian A, Sakai Y, Demay MB, St-Arnaud R, Jones G (2005) Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology 146:825–834

    Article  PubMed  CAS  Google Scholar 

  • McGuire TF, Trump DL, Johnson CS (2001) Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem 276:26365–26373

    Article  PubMed  CAS  Google Scholar 

  • Moffatt KA, Johannes WU, Miller GJ (1999) 1α,25-Dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 5:695–703

    PubMed  CAS  Google Scholar 

  • Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, Trump DL (2002) Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 72:648–659

    Article  PubMed  CAS  Google Scholar 

  • Muindi JR, Modzelewski RA, Peng Y, Trump DL, Johnson CS (2004) Pharmacokinetics of 1α,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. Oncology 66:62–66

    Article  PubMed  CAS  Google Scholar 

  • Muindi JR, Potter DM, Peng Y, Johnson CS, Trump DL (2005) Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation. Cancer Chemother Pharmacol 56:492–496

    Article  PubMed  CAS  Google Scholar 

  • Muindi JR, Johnson CS, Trump DL, Christy R, Engler KL, Fakih MG (2009) A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 65:33–40

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Muto A, Kizaki M, Yamato K, Kawai Y, Kamata-Matsushita M, Ueno H, Ohguchi M, Nishihara T, Koeffler HP, Ikeda Y (1999) 1,25-Dihydroxyvitamin D3 induces differentiation of a retinoic acid-resistant acute promyelocytic leukemia cell line (UF-1) associated with expression of p21(WAF1/CIP1) and p27(KIP1). Blood 93:2225–2233

    PubMed  CAS  Google Scholar 

  • Nakagawa K, Kawaura A, Kato S, Takeda E, Okano T (2005) 1α,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis 26:429–440

    Article  PubMed  CAS  Google Scholar 

  • Nemere I, Farach-Carson MC, Rohe B, Sterling TM, Norman AW, Boyan BD, Safford SE (2004) Ribozyme knockdown functionally links a 1,25(OH)2D3 membrane binding protein (1,25D3-MARRS) and phosphate uptake in intestinal cells. Proc Natl Acad Sci USA 101:7392–7397

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Norman AW (2006) Vitamin D receptor: new assignments for an already busy receptor. Endocrinology 147:5542–5548

    Article  PubMed  CAS  Google Scholar 

  • Odes HS, Fraser GM, Krugliak P, Lamprecht SA, Shany S (1990) Effect of cimetidine on hepatic vitamin D metabolism in humans. Digestion 46:61–64

    Article  PubMed  CAS  Google Scholar 

  • Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, Trump DL (1995) Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1:195–198

    Article  PubMed  CAS  Google Scholar 

  • Palmer HG, González-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, Muñoz A (2001) Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 154:369–387

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Parise RA, Egorin MJ, Kanterewicz B, Taimi M, Petkovich M, Lew AM, Chuang SS, Nichols M, El-Hefnawy T, Hershberger PA (2006) CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer 119:1819–1828

    Article  PubMed  CAS  Google Scholar 

  • Pendás-Franco N, García JM, Peña C, Valle N, Pálmer HG, Heinäniemi M, Carlberg C, Jiménez B, Bonilla F, Muñoz A, González-Sancho JM (2008) DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumor cell invasion and angiogenesis and is repressed by 1alpha,25-dihydroxyvitamin D3. Oncogene 27:4467–4477

    Article  PubMed  Google Scholar 

  • Petkovish M, Helvig C, Epps T (2011) CYP24A1 Regulation in health and disease. In: Feldman D, Pike JWS, Adams J (eds) Vitamin D, 3rd edn. Elsevier Science & Technology, San Diego, p 2144

    Google Scholar 

  • Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, de Rubertis G, Barbanti G, Manganelli A, Salvestrini F, Francini G (2007) Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU Int 100:775–779

    Article  PubMed  CAS  Google Scholar 

  • Plum L, DeLuca H (2010) The functional metabolism and molecular biology of vitamin D action, 2nd edn. Humana Press, New York, pp 61–97

    Google Scholar 

  • Prosser DE, Jones G (2004) Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 29:664–673

    Article  PubMed  CAS  Google Scholar 

  • Rassnick KM, Muindi JR, Johnson CS, Balkman CE, Ramnath N, Yu WD, Engler KL, Page RL, Trump DL (2008) In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. Cancer Chemother Pharmacol 62:881–891

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Rassnick KM, Muindi JR, Johnson CS, Bailey DB, Trump DL (2011) Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs. Cancer Chemother Pharmacol 67:165–171

    Article  PubMed  CAS  Google Scholar 

  • Roff A, Wilson RT (2008) A novel SNP in a vitamin D response element of the CYP24A1 promoter reduces protein binding, transactivation, and gene expression. J Steroid Biochem Mol Biol 112:47–54

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Schottker B, Ball D, Gellert C, Brenner H (2013) Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Res Rev 12:708–718

    Article  PubMed  Google Scholar 

  • Schwartz GG, Eads D, Rao A, Cramer SD, Willingham MC, Chen TC, Jamieson DP, Wang L, Burnstein KL, Holick MF, Koumenis C (2004) Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis 25:1015–1026

    Article  PubMed  CAS  Google Scholar 

  • Sinkkonen L, Malinen M, Saavalainen K, Vaisanen S, Carlberg C (2005) Regulation of the human cyclin C gene via multiple vitamin D3-responsive regions in its promoter. Nucl Acids Res 33:2440–2451

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Slapak CA, Desforges JF, Fogaren T, Miller KB (1992) Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea and calcitriol. Am J Hematol 41:178–183

    Article  PubMed  CAS  Google Scholar 

  • Srinivas S, Feldman D (2009) A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Res 29:3605–3610

    PubMed  CAS  Google Scholar 

  • Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM (2005) High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. J Urol 174:888–892

    Article  PubMed  CAS  Google Scholar 

  • Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, Yu WD, Johnson CS (2004) Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 89–90:519–526

    Article  PubMed  Google Scholar 

  • Trump DL, Deeb KK, Johnson CS (2010) Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J 16:1–9

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Vanoirbeek E, Krishnan A, Eelen G, Verlinden L, Bouillon R, Feldman D, Verstuyf A (2011) The anti-cancer and anti-inflammatory actions of 1,25(OH)2D3. Baillieres Best Pract Res Clin Endocrinol Metab 25:593–604

    Article  CAS  Google Scholar 

  • Vieth R (1990) The mechanisms of vitamin D toxicity. Bone Miner 11:267–272

    Article  PubMed  CAS  Google Scholar 

  • Wali RK, Baum CL, Sitrin MD, Brasitus TA (1990) 1,25(OH)2 vitamin D3 stimulates membrane phosphoinositide turnover, activates protein kinase C, and increases cytosolic calcium in rat colonic epithelium. J Clin Invest 85:1296–1303

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Wang Q, Yang W, Uytingco MS, Christakos S, Wieder R (2000) 1α,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res 60:2040–2048

    PubMed  CAS  Google Scholar 

  • Wang Z, Lin YS, Zheng XE, Senn T, Hashizume T, Scian M, Dickmann LJ, Nelson SD, Baillie TA, Hebert MF, Blough D, Davis CL, Thummel KE (2012a) An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. Mol Pharmacol 81:498–509

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Wang L, Song Y, Manson JE, Pilz S, Marz W, Michaelsson K, Lundqvist A, Jassal SK, Barrett-Connor E, Zhang C, Eaton CB, May HT, Anderson JL, Sesso HD (2012b) Circulating 25-hydroxyvitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes 5:819–829

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Welsh J, Wietzke JA, Zinser GM, Byrne B, Smith K, Narvaez CJ (2003) Vitamin D-3 receptor as a target for breast cancer prevention. J Nutr 133:2425S–2433S

    PubMed  CAS  Google Scholar 

  • Yanagisawa J, Yanagi Y, Masuhiro Y, Suzawa M, Watanabe M, Kashiwagi K, Toriyabe T, Kawabata M, Miyazono K, Kato S (1999) Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 283:1317–1321

    Article  PubMed  CAS  Google Scholar 

  • Yavuz B, Ertugrul DT, Cil H, Ata N, Akin KO, Yalcin AA, Kucukazman M, Dal K, Hokkaomeroglu MS, Yavuz BB, Tutal E (2009) Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther 23:295–299

    Article  PubMed  CAS  Google Scholar 

  • Yee SW, Simons C (2004) Synthesis and CYP24 inhibitory activity of 2-substituted-3,4-dihydro-2H-naphthalen-1-one (tetralone) derivatives. Bioorg Med Chem Lett 14:5651–5654

    Article  PubMed  CAS  Google Scholar 

  • Zhang X, Jiang F, Li P, Li C, Ma Q, Nicosia SV, Bai W (2005) Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Clin Cancer Res 11:323–328

    PubMed  CAS  Google Scholar 

  • Zhou W, Heist RS, Liu G, Asomaning K, Neuberg DS, Hollis BW, Wain JC, Lynch TJ, Giovannucci E, Su L, Christiani DC (2007) Circulating 25-hydroxyvitamin d levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol 25:479–485

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

All authors (Lim SJ, Kim SH) declare that they have no conflict of interest. This work was supported by the Basic Science Research Program of the National Research Foundation of Korea (2012R1A1A3010123) funded by the Ministry of Education, Science and Technology, Republic of Korea.

Author information

Authors and Affiliations

  1. Department of Bioscience and Biotechnology, Sejong University, Seoul, 143-747, Republic of Korea

    Soo-Jeong Lim

  2. College of Pharmacy and Research Institute of Pharmaceutical Science and Technology, Ajou University, Suwon, 443-749, Republic of Korea

    So Hee Kim

Authors
  1. Soo-Jeong Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. So Hee Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to So Hee Kim.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lim, SJ., Kim, S.H. Vitamin D in cancer: effects of pharmaceutical drugs on the vitamin D pharmacokinetics. Journal of Pharmaceutical Investigation 44, 317–328 (2014). https://doi.org/10.1007/s40005-014-0147-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40005-014-0147-y

Keywords

Search

Navigation